«9101112131415»Seite
15 Artikel mit Literatur, Seite 12 von 15

MEDIZIN: cme

Behandlungsstrategien beim Magenkarzinom

Treatment Strategies in Gastric Cancer
Dtsch Arztebl Int 2011; 108(41): 698-706; DOI: 10.3238/arztebl.2011.0698

Meyer, Hans-Joachim; Wilke, Hansjochen

1.Keoghley MRB: Gastrointestinal cancers in Europe. Aliment Pharmacol Ther 2003; 18: 7–30. CrossRef MEDLINE
2.Grundmann RT, Hölscher AH, Bembenek A, Bollschweiler E, Drognitz O, Feuerbach S, et al.: Diagnostik und Therapie des Magenkarzinoms – Workflow. Zentralbl Chir 2009; 134: 362–74. CrossRef MEDLINE
3.Hartgrink HH, Jansen EPM, von Grieken NCT, van de Velde CJH: Gastric Cancer. Lancet 2009; 374: 477–90. CrossRef MEDLINE
4.Moehler M, Al-Batran SE, Andus T, Anthuber M, Arends J, Arnold D, et al.: S3-Leitlinie „Magenkarzinom” – Diagnostik und Therapie der Adenokarzinome des Magens und oesophagogastralen Übergangs. Z Gastroenterol 2011; 49: 461–531. CrossRef MEDLINE
5.Englisch-Fritz C, Hünerbein M, Porschen R: Diagnostik beim Magenkarzinom. Onkologe 2008; 14: 332–8. CrossRef
6.Kwee RM, Kwee TC: Imaging in local staging of gastric cancer: A systematic review. J Clin Oncol 2007; 25: 2107–16. CrossRef MEDLINE
7.Schuhmacher C, Sendler A, Meyer H-J: Chirurgische Therapie des Magenkarzinoms. Onkologe 2008; 14: 339–49. CrossRef
8.Rabenstein T, Ell C, Feussner H: Endoskopische Resektion und minimal-invasive Verfahren beim Magenkarzinom. Onkologe 2008; 14: 350–61. CrossRef
9.Meyer H-J: The influence of case load and the extent of resection on the quality of treatment outcome in gastric cancer. EJSO 2005; 31: 595–604. MEDLINE
10.Gotoda T, Yanagisawa A, Sasako M, Ono H, Nakanishi Y, Shimoda T, et al.: Incidence of lymph node metastasis from early gastric cancer: estimation with a large number of cases at two large centers. Gastric Cancer 2000; 3: 219–25. CrossRef MEDLINE
11.Gemmill EH, McCulloch P: Systematic review of minimally invasive resection for gastro-oesophageal cancer. Br J Surg 2007; 94: 1461–7. CrossRef MEDLINE
12.Bozzetti F, Marubini E, Bonfanti G, Miceli R, Piano C, Crose N, et al.: Total versus subtotal gastrectomy: surgical morbidity and mortality rates in a multicenter Italian randomized trial. The Italian Gastointestinal Tumor Study Group. Ann Surg 1997; 226: 613–20. CrossRef MEDLINE
13.Bonenkamp JJ, Hermans J, Sasako M, van de Velde CJ, Welvaart K, Songun I, et al.: Extended lymph-node dissection for gastric cancer. N Engl J Med 1999; 340: 908–14. CrossRef MEDLINE
14.Cuschieri A, Weeden S, Fielding J, Bancewicz J, Craven J, Joypaul V, et al.: Patient survival after D1 and D2 resections for gastric cancer: long-term results of the MRC randomized surgical trial. Surgical Co-operative Group. Br J Cancer 1999; 79: 1522–30. CrossRef MEDLINE
15.Siewert JR, Böttcher K, Stein HJ, Roder JD and the German Gastric Carcinoma Study Group: Relevant prognostic factors in gastric cancer. Ten-Year results of the German Gastric Cancer Study: Ann Surg 1998; 228: 449–61. CrossRef MEDLINE
16.McCulloch P, Niita ME, Kazi H, Gama-Rodrigues JJ: Gastrectomy with extended lymphadenectomy for primary treatment of gastric cancer. Br J Surg 2005; 92: 5–13. CrossRef MEDLINE
17.Songun I, Putter H, Meershoek-Klein Kranenbarg E, Sasako M, van de Velde CJH: Surgical treatment of gastric cancer: 15-year follow-up results of the randomised nationwide Dutch D1D2 trial. Lancet Oncol 2010; 11: 439–49. CrossRef MEDLINE
18.Sasako M, Sano T, Yamamoto S, Kurokawa Y, Nashimoto A, Kurita A, et al.: D2 lymphadenectomy alone or with para-aortic nodal dissection for gastric cancer. N Engl J Med 2008; 359: 453–62. CrossRef MEDLINE
19.The GASTRIC (Global Advanced/Adjuvant Stomach Tumor Research International Collaboration) Group: Benefit of adjuvant chemotherapy for resectable gastric cancer. JAMA 2010; 303: 1729–37. MEDLINE
20.Macdonald JS, Smalley SR, Benedetti J, Hundahl SA, Estes NC, Stemmermann GN, et al.: Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med 2001; 345: 725–30. CrossRef MEDLINE
21.Cunningham D, Allum WH, Stenning SP, Thompson JN, van de Velde CJ, Nicolson M, et al.: Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 2006; 355: 11–20. CrossRef MEDLINE
22.Ychou M, Boige V, Pignon JP, Conroy T, Bouché O, Lebreton G, et al.: Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: An FNCLCC and FFCD multicenter phase III trial. J Clin Oncol 2011; 29: 1715–21. CrossRef MEDLINE
23.Stahl M, Walz MK, Stuschke M, Lehmann N, Meyer HJ, Riera-Knorrenschild J, et al.: Phase III comparison of preoperative chemotherapy compared with chemoradio-therapy in patients with locally advanced adenocarcinoma of the esophagogastric junction. J Clin Oncol 2009; 27: 851–6. CrossRef MEDLINE
24.Catalano V, Labianca R, Beretta GD, Gatta G, de Braud F, Van Cutsem E: Gastric cancer. Crit Rev Oncol Hematol 2009; 71: 127–64. CrossRef MEDLINE
25.Van Cutsem E, Kang YK, Chung HC, Shen L, Sawaki A, Lordick F, et al.: Efficacy results from the ToGA trial: a phase III study of trastuzumab added to standard chemotherapy in first-line human epidermal growth factor receptor 2 (HER2)-positive advanced gastric cancer. J Clin Oncol 2009; 27: 798s (abstract LBA4509).
«9101112131415»Seite
15 Artikel mit Literatur, Seite 12 von 15

Login

E-Mail

Passwort


Passwort vergessen?

Registrieren

Eingeloggt als

Suchen in